Abstract

Introduction: Despite improved efficacy of, and access to, combination antiretroviral therapy (cART), HIV-associated cognitive impairments remain prevalent in both children and adults. Neuropsychological tests that detect such impairment can help clinicians formulate effective treatment plans. The Kaufman Assessment Battery for Children (KABC), although developed and standardized in the United States, is used frequently in many different countries and cultural contexts to assess paediatric performance across various cognitive domains. This systematic review investigated the cross-cultural utility of the original KABC, and its 2nd edition (KABC-II), in detecting HIV-associated cognitive impairment in children and adolescents.Methods: We entered relevant keywords and MeSH terms into the PubMed, PsycInfo, EBSCOHost, ProQuest, and Scopus databases, with search limits set from 1983–2017. Two independent reviewers evaluated the retrieved abstracts and manuscripts. Studies eligible for inclusion in the review were those that (a) used the KABC/KABC-II to assess cognitive function in children/adolescents aged 2–18 years, (b) featured a definition of cognitive impairment (e.g. >2 SD below the mean) or compared the performance of HIV-infected and uninfected control groups, and (c) used a sample excluded from population on which the instruments were normed.Results and discussion: We identified nine studies (eight conducted in African countries, and one in the United Kingdom) to comprise the review’s sample. All studies detected cognitive impairment in HIV-infected children, including those who were cART-naïve or who were cART treated and clinically stable. KABC/KABC-II subtests assessing simultaneous processing appeared most sensitive. Evaluation of the methodological quality of the selected studies by two independent reviews suggested that shortcomings included reporting and selection biases.Conclusions: This systematic review provides evidence for the cross-cultural utility of the KABC/KABC-II, particularly the simultaneous processing subtests, in detecting cognitive impairment in HIV-infected children (including those who are clinically stable). Although the current results suggest there is justification for using the KABC/KABC-II primarily in East Africa, further investigation is required to explore the instrument’s utility in other HIV-prevalent regions of the globe.

Highlights

  • Despite improved efficacy of, and access to, combination antiretroviral therapy, HIV-associated cognitive impairments remain prevalent in both children and adults

  • Despite the Kaufman Assessment Battery for Children (KABC)/KABC-II’s popularity, and its widespread use in regions where HIV is highly prevalent, no study has formally evaluated whether these instruments are suited to identify cognitive impairment, across distinct and independent domains, in HIV-infected children. this systematic review aimed to determine whether the KABC/KABC-II identifies HIV-associated cognitive impairment in children who reside in cultural contexts outside of that in which the instrument was developed, standardized, and validated

  • We set out to determine, via systematic review, whether a popular, widely used, and psychometrically sound cognitive test battery, the Kaufman Assessment Battery for Children, identifies HIV-associated cognitive impairment in children who reside in cultural contexts outside of that in which the instrument was developed, standardized, and validated

Read more

Summary

Introduction

Recent global estimates suggest that 3.2 million children under 15 years of age are living with HIV. The effects of HIV infection on children’s physical growth, psychological health, and neurodevelopment ranges from mild to devastating These effects extend to cognitive development: A wealth of evidence indicates that HIV-infected children are likely to present with some form of cognitive impairment, with reported deficits in domains including attention, processing speed, language, motor skills, learning and memory, visual-spatial abilities, and executive functioning [2,3,4]. Despite the KABC/KABC-II’s popularity, and its widespread use in regions where HIV is highly prevalent (e.g. sub-Saharan Africa), no study has formally evaluated whether these instruments are suited to identify cognitive impairment, across distinct and independent domains, in HIV-infected children. (there are currently no validated neuropsychological tests, or test batteries, designed to detect such deficits in children or in adolescents.) this systematic review aimed to determine whether the KABC/KABC-II identifies HIV-associated cognitive impairment in children who reside in cultural contexts outside of that in which the instrument was developed, standardized, and validated Despite the KABC/KABC-II’s popularity, and its widespread use in regions where HIV is highly prevalent (e.g. sub-Saharan Africa), no study has formally evaluated whether these instruments are suited to identify cognitive impairment, across distinct and independent domains, in HIV-infected children. (there are currently no validated neuropsychological tests, or test batteries, designed to detect such deficits in children or in adolescents.) this systematic review aimed to determine whether the KABC/KABC-II identifies HIV-associated cognitive impairment in children who reside in cultural contexts outside of that in which the instrument was developed, standardized, and validated

Methods
Results and discussion
Limitations
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call